Navigation Links
GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
Date:11/10/2008

EBx(R) technology, to manufacture the MVA component of GeoVax's

HIV-1 vaccine. The breakthrough manufacturing technology developed

by Vivalis, through further development collaboration with GeoVax,

will create a new standard for manufacture of the MVA component of

GeoVax's HIV/AIDS vaccine. Vivalis' EBx(R) manufacturing platform,

with its increased effectiveness, superior quality and reliability,

is expected to better provide for MVA vaccine product availability

in ample quantities to meet sizeable demand and at a lesser cost.

Vivalis' vaccine manufacturing technology is based on a duck

embryonic stem cell substrate platform. Specifically, the EB66(R)

cell line provides continuous growth from a fully characterized

frozen cell bank, without necessitating fertilized embryo extraction

and processing, as with present chicken cell based technologies.

Furthermore, the EB66(R) cell line can be grown in suspension

(without the cells attached to the surface of the growth vessel) and

can be scaled up for growth in large bioreactors for commercial-

scale production of the MVA viral vaccine. The details of the final

license agreement between the parties are being negotiated and

GeoVax expects the final agreement to be executed before the end of

the year.

"On the financing front," Dr. McNally noted, "we are pleased with the financing strategy provided by the $10 million common stock purchase agreement with Fusion Capital Fund II, LLC, from which we are drawing in a judicious manner, and we are also benefiting greatly from government support in two ways -- from both the 5 year $15 million grant (approximately $3 million awarded annually) initially awarded in October 2007 by the National Institutes of Health, and also from ongoing clinical trial
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014  AuraSense Therapeutics, the pioneer in developing ... regulatory and immunotherapeutic agents, announced today that ... Therapeutics, executive leadership team as chief financial ... to joining AuraSense Therapeutics, Mr. Snyder was ... of Cellular Dynamics International Inc., where he ...
(Date:7/23/2014)... -- Having the right people at the table for significant ... and achieving clinical and operational goals. The 22 nd ... 20-22, 2014, in San Diego , ... experts discussing how partnerships have positively impacted their objectives. ... Executive Officer of Cape Regional Medical Center located in ...
(Date:7/23/2014)... , July 23, 2014 ... company of Trendlines Agtech , announced it ... Israel,s leading agricultural thermoplastics applications ... Valentis,s technology combines nanocrystalline cellulose (NCC), a ... with additional nanoparticles to produce highly improved polymeric ...
(Date:7/23/2014)... regulated information -- UCB today announced an ... with positive topline results from the latest Phase ... designed to evaluate the efficacy and safety of ... titration) compared to placebo, as adjunctive treatment in ... fully controlled despite treatment with one or two ...
Breaking Biology Technology:AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... (NYSE:,DHR) announced that Executive Vice President and Chief ... the Robert W. Baird Industrial,Conference in Chicago, IL ... CST.,The audio will be simultaneously webcast on ... manufacturer of Professional,Instrumentation, Medical Technologies, Industrial Technologies and ...
... 4 Cambrex,Corporation (NYSE: CBM ) reports third quarter 2008 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), -- Sales increased 3.2% (-1.7% ... 2007. -- Adjusted EBITDA for the quarter was up $1.7 ... last year. -- Debt, net of cash was $92.0 million ...
... PRGO ; TASE) today announced that its Board of ... on December 16, 2008 to,shareholders of record on November ... represents a ten percent increase over $0.05 per share,paid ... a leading global healthcare supplier that develops,manufactures and distributes ...
Cached Biology Technology:Cambrex Reports Third Quarter 2008 Results 2Cambrex Reports Third Quarter 2008 Results 3Cambrex Reports Third Quarter 2008 Results 4Cambrex Reports Third Quarter 2008 Results 5Cambrex Reports Third Quarter 2008 Results 6Cambrex Reports Third Quarter 2008 Results 7Cambrex Reports Third Quarter 2008 Results 8Cambrex Reports Third Quarter 2008 Results 9Cambrex Reports Third Quarter 2008 Results 10Cambrex Reports Third Quarter 2008 Results 11Cambrex Reports Third Quarter 2008 Results 12Cambrex Reports Third Quarter 2008 Results 13Cambrex Reports Third Quarter 2008 Results 14
(Date:7/23/2014)... July 23, 2014 BioCatch, the ... announced today it has been named in Gartner,s Market ... Guide replaces Gartner,s well-known Magic Quadrant for Web Fraud ... as one of several vendors to deliver passive biometric ... become a standard feature of at least 30% of ...
(Date:7/23/2014)... increase in temperature around the world by 2050, according ... Panel on Climate Change (IPCC), may be advantageous to ... in the growth of forage plants such as ... grazing in tropical countries such as Brazil., The conclusion ... the Department of Biology at the Ribeiro Preto Faculty ...
(Date:7/23/2014)... bacterial group called SUP05 will play an increasingly important ... oceans as oxygen minimum zones expand, according to research ... National Academy of Sciences . , University of British ... fjord, Canada,s Saanich Inlet, to chart how microbial community ... study paints a very detailed picture of how SUP05 ...
Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... experts have been calling for an improved database that ... conservation strategies. Botanists at the University of Bonn have ... the publication, in the Journal of Biogeography, of a ... arranged in 867 zones, known as ecoregions. "This makes ...
... Clinic researchers have found that the cause of chronic sinus ... not in the nasal and sinus tissue targeted by standard ... of Journal of Allergy and Clinical Immunology and are ... been thought worldwide about the origin of chronic sinus infection: ...
... A team of researchers at the Universitat Autònoma de ... The sensors have the same size and thickness as ... DNA chains to several minutes or a few hours, ... to many different tasks, ranging from paternity tests and ...
Cached Biology News:Scientists map the world for nature conservation 2Chronic Sinus Infection Thought To Be Tissue Issue, Mayo Clinic Scientists Show It's Snot 2New miniaturised chip dramatically reduces time taken for DNA analysis 2New miniaturised chip dramatically reduces time taken for DNA analysis 3
... Expression is a powerful application ... Utilising a novel interface, Expression makes ... incredibly simple. Expression uses the very ... standards in the way sequences are ...
... Mouse Antibody to Human Cytokeratin TYPE II ... (Type II) keratins. Including epidermal cell keratin ... 58kD, 65kD and 67kD. Broad keratin reactivity ... and cornea. Immunogen: ...
... XpressPack™ Colorimetric Detection System is intended for ... DNA generated by an in-house validated in ... target of interest. • ... is a hybridization capture assay designed to ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Biology Products: